相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Elizabeth K. O'Donnell et al.
BLOOD (2019)
Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma
Rajshekhar Chakraborty et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
Elizabeth K. O'Donnell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam et al.
LANCET HAEMATOLOGY (2018)
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the ConnectA® MM Registry
Rafat Abonour et al.
ANNALS OF HEMATOLOGY (2018)
The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial
Murielle Roussel et al.
BLOOD (2018)
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Sundar Jagannath et al.
BLOOD ADVANCES (2018)
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
P. Musto et al.
ANNALS OF ONCOLOGY (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials
Don Robinson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The Brief Pain Inventory (BPI)
Nolwenn Poquet et al.
JOURNAL OF PHYSIOTHERAPY (2016)
Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics
Robert M. Rifkin et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Ruben Niesvizky et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Content Development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): Use of Qualitative and Quantitative Methods for Scale Construction
Lynne I. Wagner et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2012)
European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses
Heinz Ludwig et al.
ONCOLOGIST (2012)
Clinimetrics corner: a closer look at the minimal clinically important difference (MCID)
Alexis Wright et al.
JOURNAL OF MANUAL & MANIPULATIVE THERAPY (2012)
A point of minimal important difference (MID): a critique of terminology and methods
Madeleine T. King
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2011)
Health related quality of life in a nationally representative sample of haematological patients
Anna T. Johnsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis
Jacques Pouchot et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences
N Gulbrandsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
分享论文
